Stock Research for GRFS

GRFS

Featured Broker: Ally Invest

Get the due diligence for another stock.

 

GRFS Stock Chart & Research Data

The GRFS chart settings shown below allow you to select time intervals of 1 min, 30 mins, an hour or by day - week - month. There is also the ability to change the GRFS chart style to candles, hollow candles, bars, lines or add various indicators. You can even add a symbol and compare history.


 


GRFS Due diligence Resources & Stock Charts

The GRFS stock resources shown below were gathered to cut back on time by allowing you to visit multiple sites at once. For your convenience each link clicked will open in a window. In addition to the individual links there is a button at the bottom that will allow you to open all the links at the same time. Note opening all links at once may not work with all browsers. Some browsers block multiple windows, to resolve this please allow that site to use pop-ups.

The Four Most Popular Resources

CNN View GRFS Detailed Price Forecast - CNN Money CNN View GRFS Detailed Summary - Google Finance
Yahoo View GRFS Detailed Summary - Yahoo! Finance Zacks View GRFS Stock Research & Analysis - Zacks.com

Stock Analysis

TradeIdeas View GRFS Trends & Analysis - Trade-Ideas Barrons View GRFS Major Holders - Barrons
NASDAQ View GRFS Call Transcripts - NASDAQ Seeking View GRFS Breaking News & Analysis - Seeking Alpha
Spotlight View GRFS Annual Report - CompanySpotlight.com OTC Report View GRFS OTC Short Report - OTCShortReport.com
TradeKing View GRFS Fundamentals - TradeKing Charts View GRFS SEC Filings - Bar Chart
WSJ View Historical Prices for GRFS - The WSJ Morningstar View Performance/Total Return for GRFS - Morningstar
MarketWatch View the Analyst Estimates for GRFS - MarketWatch CNBC View the Earnings History for GRFS - CNBC
StockMarketWatch View the GRFS Earnings - StockMarketWatch MacroAxis View GRFS Buy or Sell Recommendations - MacroAxis
Bullish View the GRFS Bullish Patterns - American Bulls Short Pains View GRFS Short Pain Metrics - ShortPainBot.com

Social Media Mentions

StockTwits View GRFS Stock Mentions - StockTwits PennyStocks View GRFS Stock Mentions - PennyStockTweets
Twitter View GRFS Stock Mentions - Twitter Invest Hub View GRFS Investment Forum News - Investor Hub
Yahoo View GRFS Stock Mentions - Yahoo! Message Board Seeking Alpha View GRFS Stock Mentions - Seeking Alpha


Financial & Transaction Holdings

SECform4 View Insider Transactions for GRFS - SECform4.com Insider Cow View Insider Transactions for GRFS - Insider Cow
CNBC View GRFS Major Holdings Summary - CNBC OTC Markets View Insider Disclosure for GRFS - OTC Markets
Yahoo View Insider Transactions for GRFS - Yahoo! Finance NASDAQ View Institutional Holdings for GRFS - NASDAQ


Stock Charts

FinViz View GRFS Stock Insight & Charts - FinViz.com StockCharts View GRFS Investment Charts - StockCharts.com
BarChart View GRFS Stock Overview & Charts - BarChart Trading View View GRFS User Generated Charts - Trading View




Latest Financial News for GRFS


A Look At The Fair Value Of Grifols SA (BME:GRF)
Posted on Thursday December 06, 2018

I am going to run you through how I calculated the intrinsic value of Grifols SA (BME:GRF) by taking the foreast future cash flows of the company and discounting them Read More...


Shanghai RAAS in tie-up talks with U.S. blood products arm of Spain's Grifols
Posted on Thursday November 22, 2018

China's Shanghai RAAS Blood Products Co Ltd is in talks to combine with a U.S. subsidiary of Spanish blood products company Grifols, the two companies said. Grifols said the talks could lead to it exchanging Grifols Diagnostic Solutions Inc, which it said was valued at around $5 billion, for newly-issued Shanghai RAAS shares. Grifols would have strategic direction of the business.


BRIEF-Shanghai RAAS Blood Products Plans To Acquire Tiancheng (Germany), Spain's Grifols Diagnostic Solutions
Posted on Thursday November 22, 2018

Nov 22 (Reuters) - Shanghai RAAS Blood Products Co Ltd : * SAYS IT PLANS TO BUY TIANCHENG (GERMANY), WHICH OWNS ABOUT 90 PERCENT OF BIOTEST AG, FOR 589 MILLION EUROS (NOT TO BUY GERMANY'S BIOTEST FOR 589 ...


Grifols demonstrates a significant reduction (61%) in the progression of moderate Alzheimer's disease using its AMBAR treatment protocol
Posted on Saturday October 27, 2018

- AMBAR, an innovative treatment approach for Alzheimer's disease (AD) using plasma science has demonstrated, with statistical significance, the ability to slow down the progression of the disease in moderate AD patients. BARCELONA, Spain, Oct. 27, 2018 /PRNewswire/ -- Presenting the study results, Antonio Páez, M.D., Grifols Medical Director and Head of the AMBAR Clinical Program confirmed that the analysis of AMBAR data in moderate patients has shown positive, highly relevant results in a cohort of patients suffering from moderate Alzheimer's disease.


Stock Market & Investing Books

Enter a stock symbol to view the stock details.